NOVAVAX REPORTS PRECLINICAL RESULTS ON VACCINE FOR PANDEMIC INFLUENZA

Novavax has reported preclinical results on its novel Virus-Like Particle (VLP) influenza vaccine.

Novavax's biological group published the detailed results in the Aug. 15 online edition of the journal Vaccine. The study demonstrates that a H9N2 influenza virus (avian flu) vaccine produced with the company's proprietary VLP technology is effective in protecting animals when challenged with live H9N2 influenza virus.

The work was completed in collaboration with the Center for Disease Control and Prevention (CDC). It involved VLP vaccines constructed from proteins produced from genes cloned from avian H9N2 influenza virus by Novavax at the CDC.